DrugPatentWatch Database Preview
Drugs in Development Information for Navitoclax
Development status for investigational drug Navitoclax: Patents, clinical trial progress, indications
Navitoclax is an investigational drug.
There have been 15 clinical trials for Navitoclax.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2013.
The most common disease conditions in clinical trials are Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and Abbott.
There are one hundred and sixty-five US patents protecting this investigational drug and one international patent.
Summary for Navitoclax
| US Patents | 165 |
| International Patents | 1,898 |
| US Patent Applications | 318 |
| WIPO Patent Applications | 111 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2013-06-01) |
| Vendors | 67 |
Recent Clinical Trials for Navitoclax
| Title | Sponsor | Phase |
|---|---|---|
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Adult Participants With Myeloproliferative Neoplasm | AbbVie | Phase 1 |
| A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis | AbbVie | Phase 2 |
| A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia | AbbVie | Phase 1 |
Clinical Trial Summary for Navitoclax
Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax
US Patents for Navitoclax
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Navitoclax | Start Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | Start Trial |
| Navitoclax | Start Trial | Antibody drug conjugates | Novartis AG (Basel, CH) | Start Trial |
| Navitoclax | Start Trial | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | Start Trial |
| Navitoclax | Start Trial | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | Start Trial |
| Navitoclax | Start Trial | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | Novartis AG (Basel, CH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Navitoclax
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Navitoclax | Canada | 2922341 | 2033-08-28 | Start Trial |
| Navitoclax | European Patent Office | 3038618 | 2033-08-28 | Start Trial |
| Navitoclax | World Intellectual Property Organization (WIPO) | 2015031608 | 2033-08-28 | Start Trial |
| Navitoclax | Argentina | 102649 | 2034-11-14 | Start Trial |
| Navitoclax | Australia | 2015347015 | 2034-11-14 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
